期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 10, 期 8, 页码 887-892出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2016.1209407
关键词
Gastric cancer; apatinib; VEGFR2; angiogenesis; chemotherapy
Introduction: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models.Areas covered: Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer.Expert commentary: Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据